Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: What is an appropriate method?

被引:27
作者
Konishi, S
Hamacher, K
Vallabhajosula, S
Kothari, P
Bastidas, D
Bander, N
Goldsmith, S
机构
[1] Cornell Univ, New York Presbyterian Hosp, Dept Radiol, Div Nucl Med, New York, NY 10021 USA
[2] Cornell Univ, New York Presbyterian Hosp, Dept Urol, Lab Urol Oncol, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
关键词
immunoreactivity; radiolabeled antibodies; cell binding assays; radioimmunotherapy;
D O I
10.1089/cbr.2004.19.706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Determination of the immunoreactive fraction (IF) of radiolabeled monoclonal antibodies (MAb) is essential to the understanding of the effects of radiolabeling and subsequent target-specific tumor localization. There has been generally no accepted method of determining the IF of MAbs. The conventional method is based on a radioimmunoassay technique in which the fraction of radiolabeled MAb bound to antigen under conditions of "antigen excess" is determined. Lindmo et al. introduced a modified method in which the IF is determined by extrapolation to conditions representing "infinite antigen excess." Although the Lindmo method, in principle, is insensitive to experimental parameters, it does not always provide a reliable estimate of IF. We, therefore, evaluated an alternate method in which percent cell bound fraction is measured under conditions of fixed antigen concentration and various dilutions of radiolabeled MAb. We developed a mathematical equation to estimate immunoreactivity. J591 MAb specific for prostate-specific membrane antigen was radiolabeled with In-111, Y-90 and (LU)-L-177 to specific activities of 1-20 mCi/mg. We compared the effect of several experimental conditions on the determination of IF using all three different methods. The Lindmo method requires careful optimization of experimental conditions for each radiolabeled MAb. The alternate method, based on a fixed antigen concentration, appears to be practical and may provide a more reliable measure of immunoreactivity.
引用
收藏
页码:706 / 715
页数:10
相关论文
共 15 条
  • [1] BUCK CR, 1978, ADV CALCULUS, P121
  • [2] DETERMINATION OF IMMUNOREACTIVE FRACTION AND KINETIC-PARAMETERS OF A RADIOLABELED MONOCLONAL-ANTIBODY IN THE ABSENCE OF ANTIGEN EXCESS
    DUX, R
    KINDLERROHRBORN, A
    LENNARTZ, K
    RAJEWSKY, MF
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 144 (02) : 175 - 183
  • [3] HAMACHER KA, J NUCL MED, V45, pP402
  • [4] ISRAELI RS, 1994, CANCER RES, V54, P1807
  • [5] AN AFFINITY COLUMN METHOD FOR DETERMINATION OF THE IMMUNOREACTIVITY OF I-131 CHIMERIC L6 MONOCLONAL-ANTIBODY AND COMPARISON TO IN-VIVO TUMOR-LOCALIZATION
    JAGODA, EM
    WEN, MD
    YOST, FJ
    SCHREIBER, GJ
    TU, JI
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 173 (02) : 191 - 201
  • [6] LINDMO T, 1986, METHOD ENZYMOL, V121, P678
  • [7] DETERMINATION OF THE IMMUNOREACTIVE FRACTION OF RADIOLABELED MONOCLONAL-ANTIBODIES BY LINEAR EXTRAPOLATION TO BINDING AT INFINITE ANTIGEN EXCESS
    LINDMO, T
    BOVEN, E
    CUTTITTA, F
    FEDORKO, J
    BUNN, PA
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1984, 72 (01) : 77 - 89
  • [8] Liu H, 1997, CANCER RES, V57, P3629
  • [9] Liu H, 1998, CANCER RES, V58, P4055